id stringlengths 14 15 | text stringlengths 51 2.13k | source stringlengths 44 128 |
|---|---|---|
975e7566ee29-5 | Authors: Mel Addison (SAEFVIC Research Nurse, Murdoch Children’s Research Institute), Georgina Lewis (Clinical Manager SAEFVIC, Murdoch Children’s Research Institute), Rachael McGuire (MVEC Education Nurse Coordinator), Teresa Lazzaro (Paediatrician, the Royal Children’s Hospital)
Reviewed by: Mel Addison (SAEFVIC Rese... | mvec.mcri.edu.au/references/pneumococcal-disease-and-vaccines/index.html |
5b3b195af40e-0 | Did you know there are additional vaccines recommended by vaccine experts that are available for private purchase? They are not free as they are not listed on the National Immunisation Program (NIP) or funded by the government. Most councils will offer some additional vaccines for purchase or alternatively all these va... | mvec.mcri.edu.au/references/recommended-additional-vaccines-for-purchase-up-to-20-years-of-age-unfunded/index.html |
5b3b195af40e-1 | Catch-up dose for any person aged under 20 years who did not receive a meningococcal C containing vaccine at 12-months of age
Young people aged 15 to 16-years or in Year 10 of secondary school as a school based vaccine program
All young people aged 15-19 years of age who have not received the vaccine at secondary schoo... | mvec.mcri.edu.au/references/recommended-additional-vaccines-for-purchase-up-to-20-years-of-age-unfunded/index.html |
5b3b195af40e-2 | Meningococcal B vaccines brands are not interchangeable.
Some local councils offer Bexsero® as a fee for service if patients wish to be protected but do not meet the criteria on the NIP. Alternatively, this vaccine is available at the GP on private prescription.
Resources:
MVEC Meningococcal disease and vaccines
MVEC: ... | mvec.mcri.edu.au/references/recommended-additional-vaccines-for-purchase-up-to-20-years-of-age-unfunded/index.html |
5b3b195af40e-3 | Children can receive a chickenpox vaccine from as young as 12 months of age. This can provide earlier protection against varicella, which may be appropriate in the context of childcare, travel or a varicella outbreak. There is no safety concern if the child still receives the dose scheduled at 18 months of age.
The min... | mvec.mcri.edu.au/references/recommended-additional-vaccines-for-purchase-up-to-20-years-of-age-unfunded/index.html |
5b3b195af40e-4 | Reviewed by: Francesca Machingaifa (SAEFVIC Research Nurse, Murdoch Children’s Research Institute) and Georgina Lewis (SAEFVIC Clinical Manager, Murdoch Children’s Research Institute)
Date: July 2020
Materials in this section are updated as new information and vaccines become available. The Melbourne Vaccine Education ... | mvec.mcri.edu.au/references/recommended-additional-vaccines-for-purchase-up-to-20-years-of-age-unfunded/index.html |
70d1bcc1c15d-0 | Vaccines are medications and like any medication, there are possible side effects or adverse events. Serious adverse events from immunisation are extremely rare. If you or your child has experienced an adverse event it should be reported to your local government health authority for follow up and management.
Please see... | mvec.mcri.edu.au/references/adverse-events-reporting-australia/index.html |
70d1bcc1c15d-1 | You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family’s personal health. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult a healthcare professional.
A B C D E F... | mvec.mcri.edu.au/references/adverse-events-reporting-australia/index.html |
6c269f10a856-0 | Hypersensitivity/allergic reactions following immunisation can be classified as:
urticarial- a red, itchy skin rash often referred to as hives, which characteristically has a central raised white wheal surrounded by an area of redness
non-urticarial rash- skin changes that don’t involve hives
angioedema- swelling in th... | mvec.mcri.edu.au/references/allergy-and-immunisation/index.html |
6c269f10a856-1 | MMR vaccine and egg allergy
Although measles and mumps vaccine viruses are cultivated in eggs, these vaccines (MMR or MMR-Varicella vaccines) contain negligible amounts of egg protein/allergen. Therefore individuals with allergy/anaphylaxis to egg can be safely immunised in the community setting without any need for ex... | mvec.mcri.edu.au/references/allergy-and-immunisation/index.html |
6c269f10a856-2 | In these instances a specialist review by an immunology/allergy/vaccination specialist to undertake a risk/benefit assessment to assess suitability for vaccination should be undertaken.
For all other allergies, including those with a history of anaphylaxis to food, drugs, venom or latex, it is recommended a routine obs... | mvec.mcri.edu.au/references/allergy-and-immunisation/index.html |
948e1d70b254-0 | What is tetanus?
Tetanus is a bacterial infection caused by the bacteria Clostridium Tetani. It commonly lives in dirt, dust and animal waste and the spores are usually introduced into the body via lacerations or puncture wounds. The spores can survive in a wound for as long as 3 months before becoming active. The most... | mvec.mcri.edu.au/references/tetanus-prone-wounds-management/index.html |
948e1d70b254-1 | Boosters doses are then scheduled to be administered at:
18 months (Infanrix®/Tripacel®)
4 years (Infanrix-IPV®/Quadracel®)
12 to 13 years of age/Year 7 high school program (Boostrix®)
A further booster dose as dTpa (Boostrix®/Adacel®) is recommended but not funded, for adults aged ≥ 50 years who have not received a do... | mvec.mcri.edu.au/references/tetanus-prone-wounds-management/index.html |
948e1d70b254-2 | An unimmunised or partially immunised person is at greatest risk of contracting tetanus. The elderly population are often included in this group due to timing of their last booster, most commonly being exposed whilst gardening.
A partially immunised person is one who has not yet completed a primary course, or has recei... | mvec.mcri.edu.au/references/tetanus-prone-wounds-management/index.html |
948e1d70b254-3 | The Royal Children’s Hospital Clinical Practice Guideline: Management of tetanus prone wound
Australian Government Department of Health and Aged Care: Changes to the National Immunisation Program schedule from July 1 2023
Author: Lynne Addlem (Immunisation Nurse, The Royal Children’s Hospital) and Rachael McGuire (Educ... | mvec.mcri.edu.au/references/tetanus-prone-wounds-management/index.html |
dd90b7f5e821-0 | At MVEC we strongly encourage people to seek answers to their questions and to be well informed with evidence-based information. We know that nearly half of all parents have some concerns about immunising their children, ranging from minor concerns to more serious degrees of vaccine hesitancy. Many people also have que... | mvec.mcri.edu.au/references/vaccine-confidence/index.html |
dd90b7f5e821-1 | Encourage them to share all their concerns before you start responding. They may even mention their most important concern last.
At this point, once they have had a chance to list their concerns, summarise them to check your understanding.
2. Acknowledge concerns and share knowledge
Not everyone is “vaccine hesitant”. ... | mvec.mcri.edu.au/references/vaccine-confidence/index.html |
dd90b7f5e821-2 | This seems obvious, but the best approach is not to judge people, correct them, or jump into battle. This just entrenches people’s beliefs and makes them defensive. And they probably won’t trust you or want to talk to you openly about this topic anymore!
How to tackle misinformation
We’ve all heard people spreadi... | mvec.mcri.edu.au/references/vaccine-confidence/index.html |
dd90b7f5e821-3 | MumBubVax: Talking about immunisation for mothers and babies
The Conversation: Everyone can be effective advocate for vaccination- here’s how
Communicating about COVID-19 vaccines and vaccine safety
World Health Organization: COVID-19 vaccines- safety surveillance manual
Pre print MJA: Communicating with patients and t... | mvec.mcri.edu.au/references/vaccine-confidence/index.html |
5e1c73d5365a-0 | Background
Swelling, redness (erythema), pain and itch at the site of injection can be a common side effect from any vaccine. Symptoms are usually mild and localised to the site of vaccination, with onset commonly occurring within the first 48 hours of vaccination and symptoms lasting 1-2 days. In some cases however, i... | mvec.mcri.edu.au/references/injection-site-reactions/index.html |
5e1c73d5365a-1 | Implications for future doses
In any age group, previous experience of an ISR is not a contraindication to future doses of vaccines and vaccine recipients are encouraged to complete the recommended vaccine schedules. Recurrence of symptoms following future vaccination may occur in some individuals but severity is not l... | mvec.mcri.edu.au/references/injection-site-reactions/index.html |
901bf60bef76-0 | Background
Pharmacist immunisers are registered pharmacists who have completed additional training that allows them to administer approved vaccines to specified patient groups. This improves vaccine accessibility for the community which is particularly important to limit the spread of vaccine preventable diseases.
Phar... | mvec.mcri.edu.au/references/pharmacist-immunisers/index.html |
901bf60bef76-1 | Pharmacy Guild of Australia, Victoria: Delivering immunisation in a community pharmacy setting
Other resources
DHHS: Pharmacist immunisers
DHHS: Pharmacist-administered vaccination services
Victorian COVID-19 Vaccination Guidelines
Victorian Pharmacist-Administered Vaccination Program Guidelines
Authors: Rachael McGuir... | mvec.mcri.edu.au/references/pharmacist-immunisers/index.html |
2d0927e368e3-0 | What is it?
Japanese encephalitis virus (JEV) is a rare but potentially serious infection caused by the flavivirus and is spread to humans through mosquito bites. It is a leading cause of vaccine-preventable encephalitis (brain infection) in Asia and the Western Pacific. It has recently been detected in piggeries in Ne... | mvec.mcri.edu.au/references/japanese-encephalitis/index.html |
2d0927e368e3-1 | Prevention
Preventing mosquito bites with physical barriers is the most effective way to avoid infection with JEV. Vaccines are also available to prevent the development of disease.
Physical barriers
Exposure to mosquito bites can be prevented in a number of ways including:
wearing long, loose fitting clothes when outd... | mvec.mcri.edu.au/references/japanese-encephalitis/index.html |
2d0927e368e3-2 | JEspect
JEspect
Age
Route
Dose
Primary course
Booster dosesΩ
≥ 2 months – < 3 years
IM
0.25ml
2 doses (28 days apart)
Single age- appropriate booster dose of either Ixiaro§/JEspect§/Imojevß is recommended if ≥ 12 months has passed since the completion of the primary course and the individual has ongoing risk of JEV ex... | mvec.mcri.edu.au/references/japanese-encephalitis/index.html |
2d0927e368e3-3 | ^ booster doses are not required for individuals who received a primary course of Imojev at ≥18 years of age, regardless of ongoing risk of exposure.
Ixiaro
Ixiaro
Age
Route
Dose
Primary course
Booster dosesΩ
≥ 2 months – < 3 years
IM
0.25ml
2 doses (28 days apart)
Single age- appropriate booster dose of either Ixiaro... | mvec.mcri.edu.au/references/japanese-encephalitis/index.html |
2d0927e368e3-4 | δ The interval can be shortened to 7 days for those aged ≥ 18 years if the individuals is at imminent risk of JEV exposure.
^ booster doses are not required for individuals who received a primary course of Imojev at ≥18 years of age, regardless of ongoing risk of exposure.
Side effects following either vaccine are usua... | mvec.mcri.edu.au/references/japanese-encephalitis/index.html |
2d0927e368e3-5 | a property that has a confirmed JE infection
a property suspected to have a JE infection
pork abbatoir or pork rendering plant
personnel who work directly with mosquitoes through surveillance, control and management, and indirectly through management of vertebrate mosquito-borne disease surveillance systems
all diagnos... | mvec.mcri.edu.au/references/japanese-encephalitis/index.html |
2d0927e368e3-6 | Other measures such as physical barriers and effective mosquito repellent are also recommended to avoid exposure.
Can pregnant women receive JEV vaccines?Women who are pregnant are recommended to receive either JEspect or Ixiaro as they are inactivated JEV vaccines.
Imojev is a live-attenuated vaccine and is therefore ... | mvec.mcri.edu.au/references/japanese-encephalitis/index.html |
2d0927e368e3-7 | The only exception to this is individuals received a primary course of Imojev when the individual was ≥ 18 years of age. In these circumstances, further booster doses are not required.
Resources
Victorian program information
Victorian Department of Health: Japanese encephalitis in Victoria
Other resources
Australian Im... | mvec.mcri.edu.au/references/japanese-encephalitis/index.html |
0be329be93f5-0 | What is it?
COVID-19 disease is caused by the highly contagious SARS-CoV-2 virus, a type of coronavirus discovered in 2019 that spread rapidly resulting in a global pandemic. Multiple strains of SARS-CoV-2 have since emerged and public health authorities continue to monitor these. The Omicron strain is currently the mo... | mvec.mcri.edu.au/references/pfizer-biontech-covid-19-vaccine/index.html |
0be329be93f5-1 | Some individuals can experience ongoing symptoms for weeks or months after their initial diagnosis, this is known as long COVID or post-COVID conditions. Symptoms can include extreme fatigue, post-exertional malaise, dyspnoea, chest pain, palpitations, fever, arthralgia (joint pain), paresthesia (pins and needles), ras... | mvec.mcri.edu.au/references/pfizer-biontech-covid-19-vaccine/index.html |
0be329be93f5-2 | How is it transmitted?
Transmission of COVID-19 is through the inhalation of virus particles which have been made airborne after an infected person coughs, sneezes, breathes, speaks or sings. Droplets or particles can contaminate surfaces and can be spread when a person touches these surfaces and then touches their nos... | mvec.mcri.edu.au/references/pfizer-biontech-covid-19-vaccine/index.html |
0be329be93f5-3 | Primary course
A primary course of vaccination is recommended for all individuals from 5 years of age. Immune competent (those with a functioning immune system) individuals should receive 2 doses given 8 weeks apart, whereas those with immunocompromise should receive 3 doses, with 8 weeks between each dose.
Children ag... | mvec.mcri.edu.au/references/pfizer-biontech-covid-19-vaccine/index.html |
0be329be93f5-4 | Vaccines brands available for use by age group
Age group Vaccine brand Comirnaty (Pfizer- original) [maroon cap] Comirnaty (Pfizer- original) [orange cap] Comirnaty (Pfizer- original) [purple cap] Comirnaty (Pfizer bivalent- original/BA.1) [grey cap] Comirnaty (Pfizer bivalent- original/BA.4/5) [grey cap] Spikevax (Mod... | mvec.mcri.edu.au/references/pfizer-biontech-covid-19-vaccine/index.html |
0be329be93f5-5 | Rare side effects
Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) are rare conditions that have been reported following administration of COVID-19 vaccines. They are most commonly associated with viral infections (including COVID-19 disease) but can also b... | mvec.mcri.edu.au/references/pfizer-biontech-covid-19-vaccine/index.html |
0be329be93f5-6 | Where can I access COVID-19 vaccines?COVID-19 vaccines can be accessed through GP clinics, some pharmacies (for vaccine recipients aged ≥ 5 years) and hospital immunisation services at Monash Children’s Hospital, the Royal Children’s Hospital and Joan Kirner Women’s and Children’s Hospital (Sunshine). To find your clos... | mvec.mcri.edu.au/references/pfizer-biontech-covid-19-vaccine/index.html |
0be329be93f5-7 | How do we complete a primary course of vaccination for children aged 6 months - ≤ 4 years who commenced their course with Spikevax (Moderna) `{`original/ancestral`}` now that it is no longer available?Immune competent children who commenced their primary course with 1 dose of Spikevax (Moderna), can complete their prim... | mvec.mcri.edu.au/references/pfizer-biontech-covid-19-vaccine/index.html |
0be329be93f5-8 | You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family’s personal health. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult a healthcare professional.
A B C D E F... | mvec.mcri.edu.au/references/pfizer-biontech-covid-19-vaccine/index.html |
ac7492ee3070-0 | What is it?
Vaccine-associated enhanced disease (VAED) is a rare phenomenon in which a (usually) more severe clinical presentation of an infection that would normally be seen in an unvaccinated person occurs in someone who has been vaccinated. Antibodies that have been generated from vaccination bind to a pathogen and ... | mvec.mcri.edu.au/references/vaccine-associated-enhanced-disease-vaed/index.html |
ac7492ee3070-1 | Assessment and evaluation
It can be difficult to distinguish between vaccine-failure (also known as breakthrough disease) and VAED. Identification of a case of VAED requires the recognition that a clinical presentation is different, atypical, modified or more severe in comparison to the natural disease presentation. Ma... | mvec.mcri.edu.au/references/vaccine-associated-enhanced-disease-vaed/index.html |
ac7492ee3070-2 | You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family’s personal health. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult a healthcare professional.
A B C D E F... | mvec.mcri.edu.au/references/vaccine-associated-enhanced-disease-vaed/index.html |
424b9a92cbcf-0 | Injected live-attenuated vaccines such as measles-mumps-rubella (MMR), measles-mumps-rubella-varicella (MMRV) and varicella (chickenpox) monovalent vaccination may be affected by circulating antibodies in immunoglobulin therapy or other blood products. This includes normal human immunoglobulin therapy for conditions li... | mvec.mcri.edu.au/references/live-attenuated-vaccines-and-immunoglobulins-or-blood-products/index.html |
424b9a92cbcf-1 | Date: July 2020
Materials in this section are updated as new information and vaccines become available. The Melbourne Vaccine Education Centre (MVEC) staff regularly reviews materials for accuracy.
You should not consider the information in this site to be specific, professional medical advice for your personal health ... | mvec.mcri.edu.au/references/live-attenuated-vaccines-and-immunoglobulins-or-blood-products/index.html |
db7ca8a7345a-0 | Travel medicine focuses on disease prevention and injury risk minimisation with advice based upon the travelling person’s individual circumstances such as the location and purpose of travel, duration and time of year, as well as any underlying medical conditions or other risk factors.
Where to get travel advice
General... | mvec.mcri.edu.au/references/travel-medicine/index.html |
db7ca8a7345a-1 | Meningococcal B (Bexsero) vaccines can also be given from 6 weeks of age (not funded on the National Immunisation Program (NIP) for all, but can be purchased privately for those who do not qualify for a funded dose)
Influenza vaccine: depending on the time of year and destination of travel, it may be advisable to recei... | mvec.mcri.edu.au/references/travel-medicine/index.html |
db7ca8a7345a-2 | Visiting friends and relatives (VFR)
VFR travel is one of the most common reasons for international travel. A VFR traveller is an immigrant who travels from the high-income country they are living in to their lower-income country of birth to visit friends or relatives. A travel consult prior to VFR travel should consid... | mvec.mcri.edu.au/references/travel-medicine/index.html |
db7ca8a7345a-3 | A B C D E F G H I J K L M N O P Q R S T U V W X Y Z | mvec.mcri.edu.au/references/travel-medicine/index.html |
8dc4a5a4c29d-0 | What is it?
COVID-19 disease is caused by the highly contagious SARS-CoV-2 virus, a type of coronavirus discovered in 2019 that spread rapidly resulting in a global pandemic. Multiple strains of SARS-CoV-2 have since emerged and public health authorities continue to monitor these. The Omicron strain is currently the mo... | mvec.mcri.edu.au/references/covid-19/index.html |
8dc4a5a4c29d-1 | Some individuals can experience ongoing symptoms for weeks or months after their initial diagnosis, this is known as long COVID or post-COVID conditions. Symptoms can include extreme fatigue, post-exertional malaise, dyspnoea, chest pain, palpitations, fever, arthralgia (joint pain), paresthesia (pins and needles), ras... | mvec.mcri.edu.au/references/covid-19/index.html |
8dc4a5a4c29d-2 | How is it transmitted?
Transmission of COVID-19 is through the inhalation of virus particles which have been made airborne after an infected person coughs, sneezes, breathes, speaks or sings. Droplets or particles can contaminate surfaces and can be spread when a person touches these surfaces and then touches their nos... | mvec.mcri.edu.au/references/covid-19/index.html |
8dc4a5a4c29d-3 | Primary course
A primary course of vaccination is recommended for all individuals from 5 years of age. Immune competent (those with a functioning immune system) individuals should receive 2 doses given 8 weeks apart, whereas those with immunocompromise should receive 3 doses, with 8 weeks between each dose.
Children ag... | mvec.mcri.edu.au/references/covid-19/index.html |
8dc4a5a4c29d-4 | Vaccines brands available for use by age group
Age group Vaccine brand Comirnaty (Pfizer- original) [maroon cap] Comirnaty (Pfizer- original) [orange cap] Comirnaty (Pfizer- original) [purple cap] Comirnaty (Pfizer bivalent- original/BA.1) [grey cap] Comirnaty (Pfizer bivalent- original/BA.4/5) [grey cap] Spikevax (Mod... | mvec.mcri.edu.au/references/covid-19/index.html |
8dc4a5a4c29d-5 | Rare side effects
Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) are rare conditions that have been reported following administration of COVID-19 vaccines. They are most commonly associated with viral infections (including COVID-19 disease) but can also b... | mvec.mcri.edu.au/references/covid-19/index.html |
8dc4a5a4c29d-6 | Where can I access COVID-19 vaccines?COVID-19 vaccines can be accessed through GP clinics, some pharmacies (for vaccine recipients aged ≥ 5 years) and hospital immunisation services at Monash Children’s Hospital, the Royal Children’s Hospital and Joan Kirner Women’s and Children’s Hospital (Sunshine). To find your clos... | mvec.mcri.edu.au/references/covid-19/index.html |
8dc4a5a4c29d-7 | How do we complete a primary course of vaccination for children aged 6 months - ≤ 4 years who commenced their course with Spikevax (Moderna) `{`original/ancestral`}` now that it is no longer available?Immune competent children who commenced their primary course with 1 dose of Spikevax (Moderna), can complete their prim... | mvec.mcri.edu.au/references/covid-19/index.html |
8dc4a5a4c29d-8 | You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family’s personal health. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult a healthcare professional.
A B C D E F... | mvec.mcri.edu.au/references/covid-19/index.html |
6f035cb73659-0 | Background
Childhood cardiac disease can be congenital or acquired. Congenital cardiac disease describes a number of conditions including malformations of the heart, major blood vessels or heart valves. Approximately 1 in 100 babies born in Australia each year will have some form of congenital heart disease. Acquired c... | mvec.mcri.edu.au/references/children-with-cardiac-disease/index.html |
6f035cb73659-1 | Pneumococcal
An additional pneumococcal conjugate vaccine (Prevenar 13®) is recommended at 6 months of age (or at diagnosis, whichever is later). A pneumococcal polysaccharide vaccine (Pneumovax 23®) should be given at 4 years of age (minimum 8 weeks post Prevenar13, whichever is later), followed by another dose at lea... | mvec.mcri.edu.au/references/children-with-cardiac-disease/index.html |
6f035cb73659-2 | Resources
MVEC: Influenza vaccine recommendations
MVEC: COVID-19 vaccination in children and adolescents
MVEC: Pneumococcal
MVEC: Needle phobia
Department of Health: Immunisation for people with medical risk conditions
Heart Kids: Congenital heart disease and COVID-19
Author: Kirsten Mitchell (SAEFVIC Research Nurse, M... | mvec.mcri.edu.au/references/children-with-cardiac-disease/index.html |
3715f46c4b54-0 | Adolescence is an important time to consider the risk of vaccine preventable diseases and the benefits of immunisation. By adolescence, immunity previously obtained from childhood vaccines can begin to decline and certain behaviours or risk factors can mean that individuals in this age group are vulnerable to other vac... | mvec.mcri.edu.au/references/adolescent-immunisation/index.html |
3715f46c4b54-1 | National Immunisation Program vaccines
Human papillomavirus (HPV)
Up to 90% of the population will be infected with a human papillomavirus (HPV) strain within their lifetime. Most HPV infections have no clinical symptoms. This means that people infected with HPV often do not know they have it and can continue transmitt... | mvec.mcri.edu.au/references/adolescent-immunisation/index.html |
3715f46c4b54-2 | Meningococcal disease is most prevalent in children aged ≤ 2 years, however there is another peak in disease among adolescents and young adults aged 15-24 years. A single dose of meningococcal ACWY (Nimenrix®) is funded for adolescents in year 10, with a catch up program available for those who missed this dose (15-19 ... | mvec.mcri.edu.au/references/adolescent-immunisation/index.html |
3715f46c4b54-3 | Influenza
Annual influenza vaccination is safe and strongly recommended for all adolescents. It is funded on the NIP for some at risk groups such as Aboriginal and Torres Strait Islander adolescents, and those with cardiac disease, severe asthma or diabetes. Those who are not funded to receive influenza vaccines and st... | mvec.mcri.edu.au/references/adolescent-immunisation/index.html |
dc5f7bded0e4-0 | Background
A vaccine mandate means that proof of vaccination, or an authorised medical exemption, is required in certain settings. Mandating is generally considered a late step in optimising vaccine uptake, as it is important to ensure vaccine access is available in an equitable way, before progressing to a mandate. Va... | mvec.mcri.edu.au/references/mandatory-vaccine-directions-in-victoria/index.html |
dc5f7bded0e4-1 | ambulance services
patient transport services engaged by a health service or Ambulance Victoria
residential aged care services that are operated by public health services
Forensicare.
For further information, refer to DH: Vaccination for healthcare workers.
Policy specific vaccine directions
No jab, no play“No jab, no ... | mvec.mcri.edu.au/references/mandatory-vaccine-directions-in-victoria/index.html |
dc5f7bded0e4-2 | Medical exemptions
Exemption to vaccination can be granted to individuals following assessment by an authorised practitioner who deems deferral of vaccination to be warranted. Exemptions may be permanent or temporary.
All medical exemptions to vaccination will be recorded on the individuals Immunisation History Stateme... | mvec.mcri.edu.au/references/mandatory-vaccine-directions-in-victoria/index.html |
dc5f7bded0e4-3 | fellows of the Royal Australian College of General Practitioners
fellows of the Australian College of Rural and Remote Medicine
on Medicare’s Vocation Register of General Practitioners
or:
a practice registrar on an approved 3GA training placement
a paediatrician
a public health physician
an infectious diseases physici... | mvec.mcri.edu.au/references/mandatory-vaccine-directions-in-victoria/index.html |
dc5f7bded0e4-4 | A B C D E F G H I J K L M N O P Q R S T U V W X Y Z | mvec.mcri.edu.au/references/mandatory-vaccine-directions-in-victoria/index.html |
dfeccbfb8538-0 | It is recommended that injected live-attenuated vaccines such as measles-mumps-rubella (MMR), measles-mumps-rubella-varicella (MMRV) and varicella (V)/(chickenpox) be deferred for a period of time after transfusion of immunoglobulin containing blood products, including red blood cells [see MVEC: Live-attenuated vaccine... | mvec.mcri.edu.au/references/live-attenuated-vaccines-in-patients-receiving-regular-red-blood-cell-transfusions/index.html |
dfeccbfb8538-1 | Summary and recommendation
Recommendations for delay in live-attenuated vaccines post blood products are based on ensuring vaccine effectiveness. However, for patients receiving regular red cell transfusions, following these recommendations will mean indefinite deferral of live-attenuated vaccines and ongoing vulnerabi... | mvec.mcri.edu.au/references/live-attenuated-vaccines-in-patients-receiving-regular-red-blood-cell-transfusions/index.html |
dfeccbfb8538-2 | Australian Red Cross Life Blood: Red cells
Zabeida A, Lebel MH, Renaud C, Cloutier M, Robitaille N. Reevaluating immunization delays after red blood cell transfusion. Transfusion 2019;59:2806-2811
Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP): General Best Practice Guidelines for Im... | mvec.mcri.edu.au/references/live-attenuated-vaccines-in-patients-receiving-regular-red-blood-cell-transfusions/index.html |
a710a8397b6a-0 | Background
Hypersensitivity/allergic reactions following immunisation can be classified as:
Urticarial – a red, itchy skin rash often referred to as hives, which characteristically has a central raised white wheal surrounded by an area of redness
Non-urticarial rash – skin changes that don’t involve hives
Angioedema – ... | mvec.mcri.edu.au/references/covid-19-vaccines-and-allergy/index.html |
a710a8397b6a-1 | A confirmed vaccine allergy usually requires a specialist consultation with a vaccine allergy specialist, often with specific testing or a vaccine challenge under supervision.
All COVID-19 immunisation hypersensitivity/allergic reactions should be reported to your state’s vaccine safety reporting service. In Victoria t... | mvec.mcri.edu.au/references/covid-19-vaccines-and-allergy/index.html |
a710a8397b6a-2 | NB: Vaccination with Vaxzevria (AstraZeneca) or Nuvaxovid (Novavax) is contraindicated in people with documented anaphylaxis to Polysorbate 80.
Latex
All of the COVID-19 vaccines available for use within Australia (Vaxzevria (AstraZeneca), Comirnaty (Pfizer), Spikevax (Moderna) and Nuvaxovid (Novavax)) can both be admi... | mvec.mcri.edu.au/references/covid-19-vaccines-and-allergy/index.html |
a710a8397b6a-3 | If a patient has a history of a known systemic mast cell activation disorder with raised mast cell tryptase that has required treatment, a referral to VicSIS prior to vaccination is recommended.
Please refer to COVID-19 vaccination – ATAGI clinical guidance on COVID-19 Vaccine in Australia in 2021 or the ASCIA Allergy,... | mvec.mcri.edu.au/references/covid-19-vaccines-and-allergy/index.html |
a710a8397b6a-4 | Investigations
Tryptase levels are recommended following potential allergic reactions as they assist with allergy assessment. Normal tryptase levels are reassuring. Tryptase levels are recommended 1 hour, 4 hours and 24 hours post reaction, however, if this is not possible, it recommended once an individual presents to... | mvec.mcri.edu.au/references/covid-19-vaccines-and-allergy/index.html |
a710a8397b6a-5 | MVEC: COVID-19 FAQs: allergies, pre-existing conditions and children
Authors: Rachael McGuire (MVEC Education Nurse Coordinator), Nigel Crawford (Director, SAEFVIC, Murdoch Children’s Research Institute), Daryl Cheng (Paediatrician, The Royal Children’s Hospital), Francesca Machingaifa (MVEC Education Nurse Coordinator... | mvec.mcri.edu.au/references/covid-19-vaccines-and-allergy/index.html |
d33ef49c9ba2-0 | What is it?
Rabies is a disease caused by exposure to saliva or nerve tissue of an animal infected with the rabies virus or other lyssavirus.
The majority of exposures occur in travellers visiting places where disease is endemic (e.g Asia, Africa)
What to look for
Initial symptoms are usually non-specific and can inclu... | mvec.mcri.edu.au/references/rabies/index.html |
d33ef49c9ba2-1 | You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family’s personal health. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult a healthcare professional.
A B C D E F... | mvec.mcri.edu.au/references/rabies/index.html |
9708f40a2564-0 | Background
Epilepsy is a disorder of the brain that leads to a person having seizures (disruptions to the electrical activity in the brain). Epilepsy can result from genetic conditions, brain injury or infection, hypoxic insult at birth, brain tumours or neurodegenerative diseases. However, the cause of epilepsy in mos... | mvec.mcri.edu.au/references/dravet-syndrome/index.html |
9708f40a2564-1 | Dravet syndrome
Dravet syndrome is a rare and severe form of infantile onset epilepsy with a prevalence of 1 in 15,500 – 40,000 children. It is caused by a genetic mutation, usually a new/non inherited (de novo) change in the sodium channel gene (SCN1A). Children with Dravet syndrome classically present with prolonged ... | mvec.mcri.edu.au/references/dravet-syndrome/index.html |
9708f40a2564-2 | Individuals with GEFS+ may experience VPS.
Immunisation
Whilst vaccination is generally recommended in individuals with Dravet syndrome and other genetic epilepsies, there is a well-reported association with febrile seizures/SE following vaccination. Seizures most commonly occur within the first 48 hours following ina... | mvec.mcri.edu.au/references/dravet-syndrome/index.html |
9708f40a2564-3 | RCH Kids health information: Febrile seizures
Epilepsy Action Australia: Seizure Types and Classification
Symonds, J. et al Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort Brain: A journal of neurology 2019 August 142(8)2303-2318
Protocol for immunisation i... | mvec.mcri.edu.au/references/dravet-syndrome/index.html |
21b9d16ff5f7-0 | What is it?
Meningococcal disease constitutes any illness caused by the bacteria Neisseria meningitidis. There are 13 known sub-types (serogroups) and of these, 5 are currently vaccine preventable (B and A, C, W, Y).
Invasive meningococcal disease (IMD) can cause meningitis (inflammation of the membrane covering the br... | mvec.mcri.edu.au/references/meningococcal-disease-and-vaccines/index.html |
21b9d16ff5f7-1 | Epidemiology
Children < 2 years of age have the highest incidence of meningococcal disease in Australia, with another peak of disease among adolescents and young adults (15-24 years). Aboriginal and Torres Strait Islander people have a much greater burden of disease than non-Indigenous people.
There are also certain me... | mvec.mcri.edu.au/references/meningococcal-disease-and-vaccines/index.html |
21b9d16ff5f7-2 | Meningococcal ACWY primary course and booster doses for healthy individualsPrimary course
Vaccine brand Course commenced at 6 weeks to ≤ 5 months of age Course commenced at 6 months to ≤ 11 months of age Course commenced at 12 months to ≤ 23 months of age Course commenced at ≥ 2 years of age Nimenrix®†3 doses (minimum ... | mvec.mcri.edu.au/references/meningococcal-disease-and-vaccines/index.html |
21b9d16ff5f7-3 | Meningococcal ACWY primary course and booster doses for those at increased risk of IMDIndividuals with specified medical conditions that increase the risk of IMD are recommended and funded to receive additional meningococcal vaccines and booster doses. These groups include:
those with defects in, or deficiency of compl... | mvec.mcri.edu.au/references/meningococcal-disease-and-vaccines/index.html |
21b9d16ff5f7-4 | † there is no registered upper age limit for the use of Menveo® or Nimenrix®.
¥ completing the course with the same vaccine brand is preferred but may not always be practical. The NIP funded 12 month dose of Nimenrix® may be used as the booster dose for those who have commenced the course at < 12 months of age.
Booster... | mvec.mcri.edu.au/references/meningococcal-disease-and-vaccines/index.html |
21b9d16ff5f7-5 | Paracetamol advice
It is widely recognised that children receiving Bexsero® are more likely to experience fever following vaccination. It is for this reason that children < 4 years of age are recommended to receive prophylactic paracetamol (15mg/kg per dose) 30 minutes prior to vaccination (or as soon as possible after... | mvec.mcri.edu.au/references/meningococcal-disease-and-vaccines/index.html |
21b9d16ff5f7-6 | N/A- not recommended in this age group.
Booster doses
Further booster doses of meningococcal B vaccines are not routinely recommended for healthy individuals.
Meningococcal B primary course and booster doses for those with increased risk of IMDIndividuals with specified medical conditions that increase the risk of IMD ... | mvec.mcri.edu.au/references/meningococcal-disease-and-vaccines/index.html |
21b9d16ff5f7-7 | Primary course
Vaccine brand Course commenced at 6 weeks to ≤ 5 months of age Course commenced at 6 months to ≤ 11 months of age Course commenced at 12 months to ≤ 9 years of age Course commenced at ≥ 10 years of age Bexsero®†4 doses (minimum 8 weeks apart, with the 4th dose given at ≥ 12 months of age/more than 8 week... | mvec.mcri.edu.au/references/meningococcal-disease-and-vaccines/index.html |
21b9d16ff5f7-8 | N/A- not recommended in this age group.
Booster doses§
Vaccine brand Where the primary course was completed at ≤ 6 years of age Where the primary course was completed at ≥ 7 years to ≤ 9 years of age Where the primary course was completed at ≥ 7 years of age Bexsero®†Give a single booster dose 3 years after completing... | mvec.mcri.edu.au/references/meningococcal-disease-and-vaccines/index.html |
21b9d16ff5f7-9 | Reviewed by: Rachael McGuire (MVEC Education Nurse Coordinator) and Nigel Crawford (Director SAEFVIC, Murdoch Children’s Research Institute)
Date: July 4, 2023
Materials in this section are updated as new information and vaccines become available. The Melbourne Vaccine Education Centre (MVEC) staff regularly reviews ma... | mvec.mcri.edu.au/references/meningococcal-disease-and-vaccines/index.html |
034fda5b3a67-0 | Background
It is widely recognised that Aboriginal and Torres Strait Islander peoples have higher rates of some vaccine preventable diseases (VPD) than non-Indigenous persons. This is not necessarily due to being of Aboriginal and/or Torres Strait Islander background, but rather due to the higher rates of underlying ch... | mvec.mcri.edu.au/references/aboriginal-and-torres-strait-islander-immunisation-recommendations/index.html |
034fda5b3a67-1 | Aboriginal and Torres Strait Islander children living in Australian Capital Territory (ACT), New South Wales (NSW), Tasmania (Tas) or Victoria (Vic) are funded for 1 dose of Prevenar 13® (13vPCV) at ages 6 weeks, 4-months and 12-months (3 doses in total). For those with a risk condition/< 28-weeks gestation an extra do... | mvec.mcri.edu.au/references/aboriginal-and-torres-strait-islander-immunisation-recommendations/index.html |
034fda5b3a67-2 | Influenza
Aboriginal and Torres Strait Islander people are three times more likely than non-Indigenous people to be admitted to hospital for influenza and pneumonia.
Annual influenza vaccination is funded on the NIP for all Aboriginal and Torres Strait Islander peoples from 6 months of age.
Meningococcal B and ACWY
In ... | mvec.mcri.edu.au/references/aboriginal-and-torres-strait-islander-immunisation-recommendations/index.html |
034fda5b3a67-3 | For more information refer to MVEC: Meningococcal.
COVID-19 vaccines
A primary course of COVID-19 vaccines are recommended for all Aboriginal and Torres Strait Islander person > 5 years of age. Additional booster doses are also recommended for certain age groups. Aboriginal and Torres Strait Islander people are priorit... | mvec.mcri.edu.au/references/aboriginal-and-torres-strait-islander-immunisation-recommendations/index.html |
034fda5b3a67-4 | ATAGI clinical guidance for COVID-19 vaccine providers
National Immunisation Program schedule for all Aboriginal and Torres Strait Islander people
NCIRS: Aboriginal and Torres Strait Islander Immunisation
Authors: Rachael McGuire (MVEC Education Nurse Coordinator), Nigel Crawford (Director SAEFVIC, Murdoch Children’s R... | mvec.mcri.edu.au/references/aboriginal-and-torres-strait-islander-immunisation-recommendations/index.html |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.